
NIPT (Non-Invasive Prenatal Screening)
Comprehensive prenatal screening for common chromosomal abnormalities from a single tube of maternal blood, starting from the 10th week of pregnancy.

Comprehensive prenatal screening for common chromosomal abnormalities from a single tube of maternal blood, starting from the 10th week of pregnancy.

Personalized expert evaluation of medications and environmental factors encountered before or during pregnancy.

Risk of congenital anomalies in consanguineous marriages and preventive steps through genetic counseling.

Selection of healthy embryos through genetic testing during IVF.

Carrier screening options tailored to couples based on family history and clinical assessment.

Expert genetic counseling for individuals at risk of hereditary diseases and carrier status.

We assess hereditary cancer risk and analyze the tumor's genetic profile to help identify targeted drugs and treatment options.

Determining hereditary breast and ovarian cancer risk through BRCA1/BRCA2 gene analysis.

Comprehensive variant analysis with clinical exome, whole genome sequencing, and disease-specific NGS panels.

Early diagnosis and carrier screening for SMA, a condition affecting motor neurons in the spinal cord.

MEFV testing for familial Mediterranean fever, interpreted alongside clinical findings.

Detailed medical history, pedigree analysis, and dysmorphological examination by a Medical Genetics specialist.

Mutation and genotype analysis in single-gene, multifactorial, and mitochondrial disorders.

Karyotyping service for numeric and structural chromosomal evaluation.

Detection of microdeletions and translocations using FISH, aCGH, and NGS methods.

Biotechnological product and service work, including the development of RT-PCR diagnostic kits.

Multigene assessment of family history and hereditary cancer predisposition.

Tumor-specific alterations and biomarker analyses supporting targeted therapy assessment.

Focused analysis of hereditary and somatic alterations associated with colorectal cancer.

Comprehensive gene panel supporting diagnostic and treatment assessment in lung cancer.

Hereditary risk genes and targeted molecular analyses associated with pancreatic cancer.

Genetic assessment of breast and ovarian cancer predisposition and tumor-specific alterations.